Safety and interactions of proton pump inhibitors: Lessons learned in millions of patients;Seguridad e interacciones de los inhibidores de la bomba de protones: Lecciones aprendidas en millones de pacientes

Gastroenterologia y Hepatologia

Volumn 33, Issue SUPPL. 1, 2010, Pages 15-21

  Esplugues, Juan V ^a,b   Martí Cabrera, Miguel ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Acid secretion; Adverse reactions; Breastfeeding; Clopidogrel; Interactions; Pharmacology; Pregnancy; Proton pump inhibitors; Safety; Toxicity; Use in special situations

Indexed keywords

ANTITHROMBOCYTIC AGENT; CIMETIDINE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ESOMEPRAZOLE; FAMOTIDINE; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ABDOMINAL PAIN; ARTICLE; BACTERIAL INFECTION; CONSTIPATION; DIARRHEA; DRUG SAFETY; EYE DISEASE; GASTRITIS; GASTROINTESTINAL REFLUX; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; HYPERGASTRINEMIA; INFECTION RISK; INTERSTITIAL NEPHRITIS; LACTATION; NAUSEA; PREGNANCY; RESPIRATORY SYSTEM; TOXIC HEPATITIS;

DRUG INTERACTIONS; HUMANS; PROTON PUMP INHIBITORS; SAFETY;

EID: 77955796382     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/S0210-5705(10)70004-2     Document Type: Article

References (46)

1. Pharm C.Q., Regal R.E., Bostwick T.R., Knauf K.S. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006, 40:1261-1266.
2. Martin R.M., Dunn N.R., Freemantle S., Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000, 50:366-372.
3. Lundell L., Miettinen P., Myrvold H.E., Pederssen S.A., Thor K., Andersson A., et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999, 117:319-326.
4. Gisbert J.P., Piqué J.M. Indicaciones y consecuencias de la erradicación de Helicobacter pylori en la enfermedad por reflujo gastroesofágico. Med Clin (Barc) 2005, 124:697-709.
5. Kuipers E.J., Lundell L., Klinkenberg-Knol E.C., Havu N., Festen H.P., Liedman B., et al. Atrophic gastritis and H. pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996, 334:1018-1022.
6. Theisen J., Nehra D., Citron D., Johansson J., Hagen J.A., Crookes P.F., et al. Supression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000, 4:50-54.
7. Trey G., Marks I.N., Louw J.A., Jaskiewicz K., Sipponen P., Novis B.H., et al. Changes in acid secretion over the years. A 30-year longitudinal study. J Clin Gastroenterol 1997, 25:499-502.
8. Vesper B.J., Jawdi A., Altman K.W., Haines G.K., Tao L., Radosevich J.A. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab 2009, 10:84-89.
9. Canani R.B., Terrin G. Gastric acidity inhibitors and the risk of intestinal infections. Curr Opin Gastroenterol 2010, 26:31-35.
10. Laheij R.J.F., Sturkenboom M.C.J., Hassing R.J., Dieleman J., Stricker B.H.C., Jansen J.B.M.J. Risk of community acquiered pneumonia and use of gastric acid suppressive drugs. JAMA 2004, 292:1955-1960.
11. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid supresion. Am J Gastroenterol 2007, 102:2047-2056.
12. Ali T., Roberts D.N., Tierney W.M. Long-term safety concerns with proton pump inhibitors. Am J Med 2009, 122:896-903.
13. Metz D.C. Clostridium difficile colitis: Wash your hands before stopping the proton pump inhibitors. Am J Gastroenterol 2008, 103:2314-2316.
14. Navarro M.A., Raei N., Torres F., Granero L., Garcia-Zaragoza E., Esplugues J.V., et al. Diferencias en la liberación de omeprazol en cuatro preparados comerciales: influencia del pH y la concentración iónica. Gastroenterol Hepatol 1998, 21:63-70.
15. Sharma V.K., Peyton B., Spears T., Raufman J.P., Howden C.W. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000, 14:887-892.
16. Yang Y.X., Lewis J.D., Epstein S., Metz D.C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947-2953.
17. Vestergaard P., Rejnmark L., Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of hip fracture. Calcif Tissue Int 2006, 79:76-83.
18. Insogna K.L. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009, 104(Suppl 2):S2-4.
19. Stewart C.A., Termanini B., Sutliff V.E., Serrano J., Yu F., Gibril F., Jensen R.T. Iron absorption in patients treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998, 12:83-98.
20. Hirschowitz B.I., Worthington J., Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008, 27:1110-1121.
21. Esplugues J.V. A pharmacological approach to gastric acid inhibition. Drugs 2005, 65(Suppl 1):7-12.
22. a ed. J. Flórez, J.A. Armijo, A. Mediavilla (Eds.).
23. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352:2211-2222.
24. Martín de Argila C. Safety of potent gastric acid inhibition. Drugs 2005, 65(Suppl 1):97-104.
25. Li X.Q., Andersson T.B., Ahlström M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 acttivities. Drug Metab Dispos 2004, 32:821-827.
26. Labenz J., Petersen K.U., Rösch W., Koelz H.R. A summary of Food and Drug and Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003, 17:1015-1019.
27. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-260.
28. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., Jilma B. Effect of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157:148e1-5.
29. Juurlink D.N., Gomez T., Ko D.T., Szmitko P.E., Austin P.C., Tu J.V., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180:713-718.
30. Ho P.M., Maddox T.M., Wang L., Fihn S.D., Jesse R.L., Peterson E.D., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944.
31. Lanas A. Inhibidores de la bomba de protones y clopidogrel en el paciente cardiovascular: ¿riesgo vascular versus riesgo gastrointestinal?. Gastroenterol Hepatol 2010, 33:1-5.
32. Laine L., Hennekens C. Proton pump inhibitor and clopidogrel interaction: Fact or fiction?. Am J Gastroenterol 2010, 105:34-41.
33. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., et al. Cytochrome P450 2C19 loss of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
34. Collet J.P., Hulot J.S., Pena A., Villard E., Esteve J.B., Silvain J., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
35. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Méneveau N., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
36. Pezalla E., Day D., Pulliadath A. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008, 51:256-260.
37. Small D.S., Farid N.A., Payne C.D., Weerakkody G.J., Li Y.G., Brandt J.T., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008, 48:475-484.
38. O'Donoghue M.L., Braunwald E., Antman E.M., Murphy S.A., Bates E.R., Rozenman Y., et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials. Lancet 2009, 374:989-997.
39. Pique J.M., Feu F., De Prada G., Ross K., Hasselgren G. Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. Clin Pharmacokinet 2002, 41:999-1004.
40. Furuta T., Ohashi K., Kamata T., Takashima M., Kosuge K., Kawasaki T., et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998, 129:1027-1030.
41. Willey J., Richter J.E. Gestational and postpartum gastroesophageal reflux disease. Womenós Health Prim Car 2001, 4:709-714.
42. Koren G., Pastuszaka A., Ito S. Drugs in pregnancy. N Eng J Med 1998, 338:1128-1131.
43. Cappell M.S., Garcia A. Gastric and duodenal ulcers during pregnancy. Gastroenterol Clin North Am 1998, 27:169-195.
44. Wilde M.I., McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid related disorders. Drugs 1994, 48:91-132.
45. Tytgat G.N., Heading R.C., Müller-Lissner S., Kamm M.N., Schölmerich J., Berstad A., et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: A consensus meeting. Aliment Pharmacol Ther 2003, 18:291-301.
46. Nikfar S., Abdollahi M., Moretti M.E., Magee L.A., Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: A meta-analysis. Dig Dis Sci 2002, 47:1526-1529.